UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2016
INNOVIVA, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
000-30319 |
|
94-3265960 |
951 Gateway Boulevard
South San Francisco, California 94080
(650) 238-9600
(Addresses, including zip code, and telephone numbers, including area code, of principal
executive offices)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On February 3, 2016, Innoviva, Inc. (the Company) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2015. A copy of the press release, which includes information regarding the Companys use of non-GAAP financial measures, is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
99.1 |
|
|
Press Release dated February 3, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INNOVIVA, INC. | |
|
| |
Date: February 3, 2016 |
By: |
/s/ Eric dEsparbes |
|
|
Eric dEsparbes |
|
|
Chief Financial Officer |
Exhibit 99.1
Innoviva reports Fourth Quarter and Full Year 2015 Financial Results
Company reports its first quarterly net income, generating $4.3 million in Q4 2015
Repurchased approximately $37 million of stock through the end of January 2016
Company to host conference call and webcast today at 5:00 p.m. EDT
SOUTH SAN FRANCISCO, Calif., February 3, 2016 Innoviva, Inc. (NASDAQ: INVA) today reported financial results for the fourth quarter and full year ended December 31, 2015. Net income for the fourth quarter of 2015 was $4.3 million or $0.04 per share, representing the Companys first quarterly net income since inception. This is compared to a net loss of $4.6 million in the third quarter or $(0.04) per share.
Royalties from sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® earned from Glaxo Group Limited (GSK) during the fourth quarter of 2015 grew by 55 percent quarter over quarter to reach $26.1 million. Income from operations increased to $17.3 million in the fourth quarter of 2015, compared to $8.4 million in the third quarter, while adjusted EBITDA for the fourth quarter of 2015 increased to $22.4 million compared to $13.4 million in the third quarter of 2015. Cash and cash equivalents, short-term investments, and marketable securities totaled $187.3 million as of December 31, 2015.
This is an exciting time for Innoviva. Weve generated our first quarterly profit since the creation of the company, maintained positive growth trends in prescriptions and market share for both RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, and ended the year in a strong position for continued growth in 2016, said Michael W. Aguiar, President and Chief Executive Officer of Innoviva. Following the spin-off of our research and development activities in 2014, we expected Innoviva to have a short path to profitability due to its lower cost profile and high revenue growth prospects. We are pleased to have achieved our goal this quarter. In addition, we repurchased approximately $37.3 million of stock through Friday, January 29, 2016 under our share repurchase program, further demonstrating our commitment to generating long-term stockholder value.
Recent Highlights
· In January 2016, the Company announced its corporate name change from Theravance, Inc. to Innoviva, Inc.
· Through January 29, 2016, Innoviva repurchased $37.3 million of stock under its previously announced $150 million share repurchase program through a combination of a modified Dutch auction tender offer (completed in December 2015) and open market purchases, with an average purchase price of $9.49 per share.
· In the fourth quarter of 2015, net sales of RELVAR®/BREO® ELLIPTA® by GSK were $154.7 million, comprised of $72.5 million in the U.S. market (an increase 79 percent from the prior quarter in the U.S.) and $82.2 million in non-U.S. markets (an increase of 43 percent from the prior quarter).
· As of December 31, 2015, RELVAR®/BREO® ELLIPTA® has been launched in 45 countries.
· In the fourth quarter of 2015, sales of ANORO® ELLIPTA® by GSK were $45.4 million, an increase of 44 percent compared to the prior quarter. Sales were $31.2 million in the U.S. market (an increase of 42 percent from the prior quarter) and $14.2 million in non-U.S. markets (an increase of 48 percent from the prior quarter).
· As of December 31, 2015, ANORO® ELLIPTA® has been launched in 38 countries.
Key Clinical and Regulatory Events for 2016
· Initial results from the Salford Lung Study in COPD are expected in the first half of 2016.
Financial Results for the Fourth Quarter and Year Ended December 31, 2015
Total revenue for the fourth quarter of 2015 was $22.8 million, which primarily resulted from royalties of $26.1 million from net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, representing a 55 percent quarter over quarter increase. The majority of royalties were driven by sales of RELVAR®/BREO® ELLIPTA®.
Research and development expenses for the fourth quarter of 2015 were $0.7 million compared with $0.5 million for the third quarter of 2015. General and administrative expenses for the fourth quarter of 2015 were $4.8 million compared with $4.6 million in the third quarter of 2015.
Income from operations reached $17.3 million in the fourth quarter of 2015, an increase of more than 100 percent over the previous quarter. Adjusted EBITDA was $22.4 million for the fourth quarter of 2015 compared to $13.4 million for the third quarter of 2015. The Company generated a net profit of $4.2 million or $0.04 per share in the fourth quarter of 2015, compared to a net loss of $4.6 million or $(0.04) per share in the third quarter.
Cash and cash equivalents, short-term investments and marketable securities totaled $187.3 million as of December 31, 2015.
Conference Call and Webcast Information
Innoviva has scheduled a conference call for today at 5:00 p.m. Eastern Standard Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting Innovivas website at www.inva.com. To listen to the live call via the Internet, please go to the website 15 minutes prior to its start to register, download and install any necessary audio software.
A replay of the conference call will be available on Innovivas website for 30 days. An audio replay will also be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 36373209.
Non-GAAP Financial Measures
To supplement the consolidated financial statements presented in accordance with generally accepted accounting principles in the United States, or GAAP, Innoviva uses the non-GAAP financial measure of adjusted EBITDA. A reconciliation of this non-GAAP financial measure to the closest GAAP financial measure is presented in the financial table below under the headings Reconciliation of Non-GAAP Financial Measures to GAAP.
Innoviva believes that the non-GAAP financial information provided in this release can assist investors in understanding and assessing Innovivas on-going operations and prospects for the future and provides an additional tool for investors to use in comparing Innovivas financial results with other companies in Innovivas industry or with similar operating profiles. Adjusted EBITDA is used as a supplemental financial measure by Innovivas management and also occasionally by external users of its financial statements, such as investors, commercial banks, research analysts and others, to assess:
· the financial performance of Innovivas assets without regard to financing methods, capital structure or historical cost basis;
· the ability of Innovivas assets to generate cash sufficient to pay interest costs and support its indebtedness; and
· Innovivas operating performance and return on investment as compared to those of other companies, without regard to financing or capital structures.
Adjusted EBITDA is determined by taking GAAP net income from operations and adding back stock-based compensation expense from continuing operations, depreciation expense from continuing operations and amortization of capitalized fees paid to a related party. Innovivas method of computing adjusted EBITDA may not be the same method used to compute similar measures reported by other companies.
Adjusted EBITDA should not be considered in isolation or as a substitute to net income (loss), income (loss) from operations, cash flows from operating activities or any other measure of financial performance presented in accordance with GAAP. Adjusted EBITDA is not intended to represent cash flow and does not represent the measure of cash available for distribution. The principal limitation of this non-GAAP financial measure is that it excludes significant elements that are required by GAAP to be recorded in Innovivas consolidated financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management in determining these non-GAAP financial measures. In order to compensate for these limitations, management of Innoviva presents its non-GAAP financial measures in connection with its GAAP results. Investors are encouraged to review the reconciliation of Innovivas non-GAAP financial measures to their most directly comparable GAAP financial measure.
About Innoviva
Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innovivas portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innovivas website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
Note Regarding Share Repurchase Program
The companys discussion of its share repurchase program does not obligate the company to repurchase any specific dollar amount or number of its shares of common stock. The company will determine when, if and how to proceed with any repurchase transactions under the program, as well as the amount of any such repurchase transactions, based upon, among other things, the results of the tender offer and the companys evaluation of its liquidity and capital needs (including for strategic and other opportunities), its business, results of operations, and financial position and prospects, general financial, economic and market conditions, prevailing market prices for the companys shares of common stock, corporate, regulatory and legal requirements, and other conditions and factors deemed relevant by the companys management and Board of Directors from time to time. The share repurchase program may be suspended or discontinued at any time. There can be no assurance as to the actual volume of share repurchases in any given period or over the term of the program, if any, or as to the manner or terms of any such repurchases. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.
Forward Looking Statements
This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks, uncertainties and assumptions. Examples of such statements include statements relating to: payor coverage, the strategies, plans and objectives of the company, the status and timing of clinical studies, data analysis and communication of results, the potential benefits and mechanisms of action of product candidates, expectations for product candidates through development and commercialization, the timing of seeking regulatory approval of product candidates, and projections of revenue, expenses and other financial items. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK, delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective, dependence on third parties to conduct its clinical studies, delays or failure to achieve and maintain regulatory
approvals for product candidates, and risks of collaborating with third parties to discover, develop and commercialize products. Other risks affecting Innoviva are described under the headings Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations contained in Innovivas Annual Report on Form 10-K for the year ended December 31, 2014 and Innovivas Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, which are on file with the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. Additional factors may be described in those sections of Innovivas Annual Report on Form 10-K for the year ended December 31, 2015, to be filed with the SEC in the first quarter of 2016. In addition to the risks described above and in Innovivas other filings with the SEC, other unknown or unpredictable factors also could affect Innovivas results. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Contact Information:
Eric dEsparbes
Sr. Vice President and Chief Financial Officer
650-238-9640
investor.relations@inva.com
(INVA-F)
INNOVIVA, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
|
|
Three Months Ended |
| ||||
|
|
December 31, |
|
September 30, |
| ||
|
|
2015 |
|
2015 |
| ||
|
|
(unaudited) |
| ||||
Revenue: |
|
|
|
|
| ||
Royalty revenue from a related party, net |
|
$ |
22,615 |
|
$ |
13,341 |
|
Revenue from collaborative arrangements from a related party, net |
|
221 |
|
221 |
| ||
Total revenue |
|
22,836 |
|
13,562 |
| ||
|
|
|
|
|
| ||
Operating expenses: |
|
|
|
|
| ||
Research and development |
|
722 |
|
547 |
| ||
General and administrative |
|
4,821 |
|
4,581 |
| ||
Total operating expenses |
|
5,543 |
|
5,128 |
| ||
|
|
|
|
|
| ||
Income from operations |
|
17,293 |
|
8,434 |
| ||
|
|
|
|
|
| ||
Other income (expense), net |
|
3 |
|
(45 |
) | ||
Interest income |
|
52 |
|
90 |
| ||
Interest expense |
|
(13,047 |
) |
(13,063 |
) | ||
|
|
|
|
|
| ||
Net income (loss) |
|
$ |
4,301 |
|
$ |
(4,584 |
) |
|
|
|
|
|
| ||
Basic earnings per share |
|
$ |
0.04 |
|
$ |
(0.04 |
) |
|
|
|
|
|
| ||
Shares used in computing basic earnings per share |
|
115,184 |
|
115,787 |
| ||
|
|
|
|
|
| ||
Cash dividends declared per share |
|
$ |
|
|
$ |
0.25 |
|
INNOVIVA, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
|
|
Three Months Ended |
|
Fiscal Years Ended |
| ||||||||
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
| ||||
|
|
(unaudited) |
|
(unaudited) |
| ||||||||
Revenue: |
|
|
|
|
|
|
|
|
| ||||
Royalty revenue from a related party, net |
|
$ |
22,615 |
|
$ |
7,009 |
|
$ |
53,064 |
|
$ |
7,351 |
|
Revenue from collaborative arrangements from a related party, net |
|
221 |
|
271 |
|
885 |
|
1,082 |
| ||||
Total revenue (1) |
|
22,836 |
|
7,280 |
|
53,949 |
|
8,433 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Operating expenses: |
|
|
|
|
|
|
|
|
| ||||
Research and development (2) |
|
722 |
|
777 |
|
2,619 |
|
7,498 |
| ||||
General and administrative (2) |
|
4,821 |
|
6,373 |
|
19,750 |
|
34,864 |
| ||||
Total operating expenses |
|
5,543 |
|
7,150 |
|
22,369 |
|
42,362 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Income (Loss) from operations |
|
17,293 |
|
130 |
|
31,580 |
|
(33,929 |
) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Other income (expense), net |
|
3 |
|
(3,607 |
) |
1,120 |
|
(3,272 |
) | ||||
Interest income |
|
52 |
|
117 |
|
343 |
|
563 |
| ||||
Interest expense |
|
(13,047 |
) |
(12,566 |
) |
(51,803 |
) |
(36,892 |
) | ||||
Income (loss) from continuing operations before income taxes |
|
4,301 |
|
(15,926 |
) |
(18,760 |
) |
(73,530 |
) | ||||
Income tax benefit |
|
|
|
|
|
|
|
|
| ||||
Income (loss) from continuing operations, net of tax |
|
4,301 |
|
(15,926 |
) |
(18,760 |
) |
(73,530 |
) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Loss from discontinued operations |
|
|
|
|
|
|
|
(94,934 |
) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Net income (loss) |
|
$ |
4,301 |
|
$ |
(15,926 |
) |
$ |
(18,760 |
) |
$ |
(168,464 |
) |
|
|
|
|
|
|
|
|
|
| ||||
Basic earnings per share: |
|
|
|
|
|
|
|
|
| ||||
Continuing operations |
|
$ |
0.04 |
|
$ |
(0.14 |
) |
$ |
(0.16 |
) |
$ |
(0.66 |
) |
Discontinued operations |
|
|
|
|
|
|
|
(0.84 |
) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Shares used in computing basic earnings per share |
|
115,184 |
|
114,342 |
|
115,372 |
|
112,059 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Cash dividends declared per common share |
|
$ |
|
|
$ |
0.25 |
|
$ |
0.75 |
|
$ |
0.50 |
|
(1) Revenue is comprised of the following (in thousands):
|
|
Three Months Ended |
|
Fiscal Years Ended |
| ||||||||
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
| ||||
|
|
(unaudited) |
|
(unaudited) |
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||
Royalties from a related party |
|
$ |
26,071 |
|
$ |
10,464 |
|
$ |
66,887 |
|
$ |
18,417 |
|
Amortization of capitalized fees paid to a related party |
|
(3,456 |
) |
(3,455 |
) |
(13,823 |
) |
(11,066 |
) | ||||
Royalty revenue |
|
22,615 |
|
7,009 |
|
53,064 |
|
7,351 |
| ||||
Strategic alliance - MABA program |
|
221 |
|
271 |
|
885 |
|
1,082 |
| ||||
Total revenue from a related party |
|
$ |
22,836 |
|
$ |
7,280 |
|
$ |
53,949 |
|
$ |
8,433 |
|
(2) Amounts include stock-based compensation expense as follows (in thousands):
|
|
Three Months Ended |
|
Fiscal Years Ended |
| ||||||||
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
| ||||
|
|
(unaudited) |
|
(unaudited) |
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||
Research and development |
|
$ |
349 |
|
$ |
192 |
|
$ |
1,036 |
|
$ |
2,781 |
|
General and administrative |
|
1,301 |
|
1,185 |
|
5,837 |
|
12,980 |
| ||||
Discontinued operations |
|
|
|
|
|
|
|
11,629 |
| ||||
Total stock-based compensation expense |
|
$ |
1,650 |
|
$ |
1,377 |
|
$ |
6,873 |
|
$ |
27,390 |
|
INNOVIVA, INC.
Consolidated Balance Sheets
(in thousands)
|
|
December 31, |
|
December 31, |
| ||
|
|
2015 |
|
2014 |
| ||
|
|
(unaudited) |
|
(1) |
| ||
|
|
|
|
|
| ||
Assets |
|
|
|
|
| ||
Cash, cash equivalents and marketable securities |
|
$ |
187,283 |
|
$ |
283,354 |
|
Other current assets |
|
27,042 |
|
11,684 |
| ||
Property and equipment, net |
|
221 |
|
324 |
| ||
Capitalized fees paid to a related party, net |
|
194,368 |
|
208,191 |
| ||
Other assets |
|
15,158 |
|
18,101 |
| ||
Total assets |
|
$ |
424,072 |
|
$ |
521,654 |
|
|
|
|
|
|
| ||
Liabilities and stockholders deficit |
|
|
|
|
| ||
Other current liabilities |
|
$ |
4,695 |
|
$ |
4,067 |
|
Payable to Theravance Biopharma, Inc. |
|
|
|
1,056 |
| ||
Accrued interest payable |
|
7,911 |
|
7,551 |
| ||
Deferred revenue |
|
3,984 |
|
4,870 |
| ||
Convertible subordinated notes |
|
255,109 |
|
255,109 |
| ||
Non-recourse notes payable, due 2029 |
|
493,162 |
|
470,527 |
| ||
Other long-term liabilities |
|
1,856 |
|
1,823 |
| ||
|
|
|
|
|
| ||
Stockholders deficit |
|
(342,645 |
) |
(223,349 |
) | ||
|
|
|
|
|
| ||
Total liabilities and stockholders deficit |
|
$ |
424,072 |
|
$ |
521,654 |
|
(1) The selected consolidated balance sheet amounts at December 31, 2014 are derived from audited financial statements.
INNOVIVA, INC.
Reconciliation of GAAP to Non-GAAP Operating Results
(in thousands)
|
|
Three Months Ended |
| ||||
|
|
December |
|
September |
| ||
|
|
31, |
|
30, |
| ||
|
|
(unaudited) |
| ||||
Reconciliation from GAAP net income from operations to adjusted EBITDA: |
|
|
|
|
| ||
GAAP net income from operations |
|
$ |
17,293 |
|
$ |
8,434 |
|
Non-GAAP adjustments: |
|
|
|
|
| ||
Stock-based compensation |
|
1,650 |
|
1,468 |
| ||
Depreciation |
|
28 |
|
28 |
| ||
Amortization of capitalized fees paid to a related party |
|
3,456 |
|
3,455 |
| ||
|
|
|
|
|
| ||
Adjusted EBITDA |
|
$ |
22,427 |
|
$ |
13,385 |
|
INNOVIVA, INC.
Reconciliation of GAAP to Non-GAAP Operating Results
(in thousands)
|
|
Three Months Ended |
|
Fiscal Years Ended |
| ||||||||
|
|
December 31, |
|
December 31, |
| ||||||||
|
|
2015 |
|
2014 |
|
2015 |
|
2014 |
| ||||
|
|
(unaudited) |
|
(unaudited) |
| ||||||||
Reconciliation from GAAP net income (loss) from operations to adjusted EBITDA: |
|
|
|
|
|
|
|
|
| ||||
GAAP net income (loss) from operations |
|
$ |
17,293 |
|
$ |
130 |
|
$ |
31,580 |
|
$ |
(33,929 |
) |
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
| ||||
Stock-based compensation from continuing operations |
|
1,650 |
|
1,377 |
|
6,873 |
|
15,761 |
| ||||
Depreciation from continuing operations |
|
28 |
|
|
|
110 |
|
|
| ||||
Amortization of capitalized fees paid to a related party |
|
3,456 |
|
3,455 |
|
13,823 |
|
11,066 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Adjusted EBITDA |
|
$ |
22,427 |
|
$ |
4,962 |
|
$ |
52,386 |
|
$ |
(7,102 |
) |